原著 |
|
|
|
|
新辅助化疗前后激素受体变化的乳腺癌患者辅助内分泌治疗的疗效 |
夏光发1,2, 朱娟英2, 袁军2, 曹博2, 唐婕2, 陈益定1 |
1. 浙江大学医学院附属第二医院肿瘤外科, 浙江 杭州 310006;
2. 嘉兴市妇幼保健院乳腺科, 浙江 嘉兴 314000 |
|
Efficacy of adjuvant endocrine therapy in breast cancer patients with a positive-to-negative switch of hormone receptor status after neoadjuvant chemotherapy |
XIA Guangfa1,2, ZHU Juanying2, YUAN Jun2, CAO Bo2, TANG Jie2, CHEN Yiding1 |
1. Department of Surgical Oncology, the Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310006, China;
2. Department of Breast Surgery, Jiaxing Maternity and Child Health Care Hospital, Jiaxing 314000, China |
[1] |
BURCOMBE RJ, MAKRIS A, RICHMAN PI, et al. Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer[J]. Br J Cancer, 2005, 92(1):147-155.
|
[2] |
HIRATA T, SHIMIZU C, YONEMORI K, et al. Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer[J]. Br J Cancer, 2009, 101(9):1529-1536.
|
[3] |
JAIN V, LANDRY M, LEVINE EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma[J]. Am Surg, 1996, 62(2):162-165.
|
[4] |
TACCA O, PENAULT-LLORCA F, ABRIAL C, et al. Changes in and prognostic value of hormone receptor status in a series of operable breast cancer patients treated with neoadjuvant chemotherapy[J]. Oncologist, 2007, 12(6):636-643.
|
[5] |
EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours:revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2):228-247.
|
[6] |
CONNOR CS, TAWFIK OW, JOYCE AJ, et al. A comparison of prognostic tumor markers obtained on image-guided breast biopsies and final surgical specimens[J]. Am J Surg, 2002, 184(4):322-324.
|
[7] |
TAUCHER S, RUDAS M, MADER RM, et al. Prognostic markers in breast cancer:the reliability of HER2/neu status in core needle biopsy of 325 patients with primary breast cancer[J]. Wien Klin Wochenschr, 2004, 116(1-2):26-31.
|
[8] |
MUELLER-HOLZNER E, FINK V, FREDE T, et al. Immunohistochemical determination of HER2 expression in breast cancer from core biopsy specimens:a reliable predictor of HER2 status of the whole tumor[J]. Breast Cancer Res Treat, 2001, 69(1):13-19.
|
[9] |
CHEN X, YUAN Y, GU Z, et al. Accuracy of estrogen receptor, progesterone receptor, and HER2 status between core needle and open excision biopsy in breast cancer:a meta-analysis[J]. Breast Cancer Res Treat, 2012, 134(3):957-967.
|
[10] |
ZHANG N, MORAN MS, HUO Q, et al. The hormonal receptor status in breast cancer can be altered by neoadjuvant chemotherapy:a meta-analysis[J]. Cancer Invest, 2011, 29(9):594-598.
|
[11] |
GOLDHIRSCH A, WOOD WC, COATES AS, et al. Strategies for subtypes-dealing with the diversity of breast cancer:highlights of the St. gallen international expert consensus on the primary therapy of early breast cancer 2011[J]. Ann Oncol, 2011, 22(8):1736-1747.
|
[12] |
PEROU C M, SØRLIE T, EISEN M B, et al. Molecular portraits of human breast tumours[J]. Nature, 2000, 406(6797):747-752.
|
[13] |
SØRLIE T, PEROU C M, TIBSHIRANI R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications[J]. Proc Natl Acad Sci U S A, 2001, 98(19):10869-10874.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|